Home – Page 13 – The Cancer Letter

Issue 18 - May 1, 2020

TCL46-18 (788 downloads)

Real-World Evidence
COVID-19 vs. community oncology: Flatiron’s data provides first damage assessment
Community oncology practices in the United States are reeling from a sharp decrease in business—whether you look at new patients, chemotherapy visits, or non-chemo visits—the result of reduced activity and stay-at-home orders across the country to mitigate the spread of SARS-CoV-2.
Conversation with The Cancer Letter
NSCLC patients getting checkpoint inhibitors more likely to develop pneumonitis, Syapse-FDA-Aurora study finds
Patients with lung cancer and a history of pneumonitis are more likely to develop treatment-associated pneumonitis later, especially in the course of receiving immune checkpoint inhibitor therapy, according to a new study by Syapse, FDA, and Advocate Aurora Health.
Conversation with The Cancer Letter
Skip Burris: These few months are going to shape health care in the coming years
The COVID-19 pandemic will change the structure and economics of clinical care and clinical trials in cancer, said Howard “Skip” Burris, president of clinical operations and chief medical officer of Sarah Cannon, the Cancer Institute of HCA Healthcare.
AACR data from China and Europe amount to “two different messages” for cancer patients with COVID-19
Are COVID-19 patients with cancer at a greater risk of dying than non-cancer patients? Depends on whom you ask.
Conversation with The Cancer Letter
With 61,000 people registered, first-ever virtual AACR annual meeting “enthusiastically received”
Nobody knew how to even begin to predict the number of people who would register for the first-ever virtual annual meeting of the American Association for Cancer Research.
Remdesivir established as standard of care for COVID-19, Fauci declares
FDA issues Emergency Use Authorization
Early data from two randomized phase III studies of the antiviral drug remdesivir make it a viable treatment for COVID-19.
Guest Editorial
Under the onslaughts of COVID-19, Montefiore deployed a PPE strategy for patients—PREVENT/PROTECT/ENABLE
March 1, 2020, started as a good day at the Montefiore Einstein Center for Cancer Care in New York.
Guest Editorial
The pandemic of COVID-19 and its effect on clinical trials in the community
How do we move forward?
This pandemic has affected a lot of people, both physicians and patients, physically as well as emotionally.
Guest Editorial
Cancer doesn’t wait—we are treating cancer patients now
As part of responding to the COVID-19 pandemic, hospitals across the nation had dramatically reduced their surgery schedules when UC Davis cancer patient Marlene Blake had surgery for breast cancer in March.
Dafna Bar-Sagi, Arul Chinnaiyan, Carl June, Christopher Lima, Miriam Merad, and John Schiller are among newly elected NAS members
The National Academy of Sciences announced the election of 120 members and 26 international members in recognition of their distinguished and continuing achievements in original research.
Covid-19 Updates
- FDA grants Emergency Use Authorization for novel, non-implanted device to wean patients off mechanical ventilation
- TGen seeks volunteers for COVID-19 immunity study
- J&J and Emergent Bio collaborate on coronavirus vaccine candidate
In Brief
- Kristin Brill named enterprise director of Breast Oncology at SKCC
- UCLA researchers receive $2.8M NCI grant to develop blood-based test for liver transplant candidate selection
- 2020 Stovall award nominations due May 1
Clinical Roundup
- Phase III trial evaluating Libtayo in NSCLC halted because of significant OS improvement
- Lynparza demonstrates OS benefit in phase III prostate cancer trial
- GARNET study demonstrates potential of dostarlimab to treat recurrent or advanced endometrial cancer
- MD Anderson, Ipsen advance therapy with potential benefit for patients with lung, ovarian cancer
- Study: Disruptions in health insurance coverage are common, and affect cancer care and survival
- AI may help brain cancer patients avoid biopsy
- Mouse model study shows promise in treatment of medulloblastoma and ependymoma
Drugs & Targets
- FDA approves GSK’s PARP inhibitor Zejula for first-line maintenance of advanced ovarian cancer
- FDA grants accelerated approval to new dosing regimen for Keytruda
- FDA grants Mobocertinib Breakthrough Therapy Designation in NSCLC designation
Clarification

Issue 17 - Apr 24, 2020

TCL46-17 (867 downloads)

Remdesivir, IL inhibitors emerge as frontrunners in race to treat COVID-19
Phase III results for remdesivir expected within weeks
Experts in infectious diseases and investors on Wall Street are honing in on two potential treatments for COVID-19: interleukin inhibitors and remdesivir.
Conversation with The Cancer Letter
Berry: “Designing clinical trials doesn’t have high priority when there’s no pandemic. And then, when there’s a pandemic, there’s panic”
After a series of global epidemics, Don Berry has spent the past several years preparing for a serious pandemic that would be caused by yet another viral pathogen.
Guest Editorial
When disparities widen: COVID-19 in minority patients with cancer
In late December, rumors regarding a dangerous virus that originated in a seafood market in Wuhan, China started spreading across the world. At the time, all we knew was that the virus resembled the severe acute respiratory syndrome, better known as SARS, and that it was aggressive and deadly.
Guest Editorial
COVID-Lung Cancer Consortium:
An example of how the lung cancer community came together in challenging times
The COVID-19 pandemic has created a host of diagnostic, treatment, and follow-up problems for patients with cancer of all types, and this is particularly true for patients with lung cancer, their families, and health care providers.
Conversation with The Cancer Letter
Feist-Weiller mammography vans repurposed to screen for COVID-19 in northwest Louisiana
At least for now, Feist-Weiller Cancer Center at the Louisiana State University Health Sciences Center at Shreveport has repurposed the three vans that were used to provide cancer screening and essential health care to medically underserved communities.
Conversation with The Cancer Letter
Tulane Cancer Center chips away at the “digital divide” that keeps the underserved from benefiting from telemedicine
In the past, few patients had Oliver Sartor’s personal cell phone number.
Since the COVID-19 outbreak in New Orleans, Sartor, professor of medicine and medical director of Tulane Cancer Center, C.E. and Bernadine Laborde Professor of Cancer Research, gives out his number to all patients as part of telehealth visits.
Conversation with The Cancer Letter
As COVID-19 peaks in San Antonio, Ruben Mesa predicts gradual reopening
News coverage of the COVID-19 pandemic in New York has lent urgency to social distancing efforts in San Antonio and South Texas, likely flattening the curve.
COVID-19 Updates
- FDA issues advisory on off-label use of hydroxychloroquine and chloroquine
- AACI annual meeting goes virtual
- Reagan-Udall Foundation and Friends of Cancer Research form COVID-19 Evidence Accelerator focused on RWE
- Western NY researchers study COVID-19 using NGS to identify immune response biomarkers
- Invitae develops tools to support telemedicine
- Kennedy, former FDA commissioner and Stanford president, dies of COVID-19
- FAQs and Guidances
In Brief
- ASCO announces 2020 awards
- Serody and Basch named to leadership roles at UNC
- Poynter, Harki appointed to leadership team at Masonic Cancer Center
- American Heart Association grants $17 million for studies on health impact of e-cigarettes and nicotine on youth
Clinical Roundup
- Phase III CheckMate-743 study of Opdivo and Yervoy meets primary OS endpoint in mesothelioma
- Phase III CheckMate -9ER meets primary PFS endpoint in RCC
- New targeted agent produces responses in trial with patients with uterine serous carcinoma
- RVD Therapy shows substantial benefit in large myeloma study
- Cue Biopharma and Merck to evaluate CUE-101 + Keytruda in head and neck indication
Drugs & Targets
- FDA approves Tukysa in breast cancer indication
- FDA grants accelerated approval for Trodelvy in previously-treated metastatic TNBC
- FDA approves first targeted treatment for patients with cholangiocarcinoma
- FDA approves Imbruvica in CLL/SLL indication
- FDA approves Keytruda companion diagnostic

Issue 16 - Apr 17, 2020

TCL46-16 (787 downloads)

Lowy: “Our patients are counting on us, and we must not let them down”
NCI Frederick Lab takes aim at COVID-19
NCI’s Frederick National Laboratory for Cancer Research has launched three initiatives focused on SARS-CoV-2.
Doroshow: NCI to accrue patients for COVID-19 longitudinal cohort
Ongoing trials see significant decrease in accrual
NCI is building a nationwide cohort of cancer patients with COVID-19 at over 1,000 sites across the institute’s clinical trials networks and at NCI-designated cancer centers.
NCI Director’s Report
Sharpless: NCI is fully operational, we have a moral obligation to help in the COVID-19 pandemic response
In spite of disruptions caused by the coronavirus pandemic, NCI continues to review grants, disburse funds, and support extramural research, said NCI Director Ned Sharpless.
As treatments get cancelled because of COVID-19, patients worry about adequacy of care
To prevent the spread of COVID-19, oncologists are either limiting or canceling adjuvant care, in effect staging a population-level experiment.
American Cancer Society announces a wave of furloughs and layoffs as COVID-19 constricts fundraising
The American Cancer Society earlier this week announced immediate furloughs and layoffs of its staff citing “a significant financial hardship” triggered by the novel coronavirus.
Guest Editorial
Amid COVID-19 pandemic, cancer community responds to fill data gap
As clinicians in a medical specialty that relies on evidence to guide treatment plans for individuals with cancer, we face an unfortunate dearth of data to help steer us during the coronavirus pandemic.
Guest Editorial
Cancer care continues during COVID-19 pandemic—with new tools and old challenges
While the news these days is rightly focused on hospitals and the government fighting public enemy number one, aka COVID-19 (the novel coronavirus), independent community oncology practices continue to treat and comfort patients who are at war with that insidious disease we call cancer.
Conversation with The Cancer Letter
Lichtenfeld: COVID-19 exposed weaknesses in the U.S. health care system
How has the COVID-19 pandemic affected oncology?
What will the long-term impact be?
COVID-19 Updates
- AstraZeneca trial to test Calquence in COVID-19 patients
- Clinical trial accruals at OneOncology increase in the face of COVID-19
- American Cancer Society opens COVID-19 tracking study
- Research!America urges Congress to modify budget caps, increase FY21 funding for health agencies
- NAS, NAE, and NAM presidents: U.S. funding for WHO should not be interrupted during COVID-19 pandemic
- White House expands coverage for essential diagnostic services
- Bipartisan bill proposes telehealth expansion
- Nebraska Medical Center develops infectious aerosol capture mask to protect health care workers
- FDA authorizes blood purification device to treat COVID-19
- Adolescent, young adult cancer non-profits provide guidance on COVID-19
- FAQs and Guidances
In Brief
- J. Alan Diehl named deputy director and chief operating officer of Case CCC
- Andres F. Correa joins Fox Chase Cancer Center
- Esther Welkowsky named VP, clinical operations, at Elicio Therapeutics
Clinical Roundup
- Elicio Therapeutics and NCI study ELI-002 mutant KRAS targeting mechanism
- ACS study: JUUL sales bounced back within weeks of self-imposed flavor ban
- Chronic stress can impact response to radiation therapy
Drugs & Targets
- FDA approves Koselugo for neurofibromatosis type 1
- FDA approves mitomycin for low-grade upper tract urothelial cancer
- Ontruzant, biosimilar of Herceptin, introduced in the U.S.

Page 13 of 118« First «...9 10 11 121314 15 16 17 18...30 40 50 60 70 80 90 100 110...»Last »